Literature DB >> 10219335

Fungal colonization and infection in children with acute leukemia and lymphoma during induction therapy.

S Gözdaşoĝlu1, M Ertem, Z Büyükkeçeci, S Yavuzdemir, S Bengisun, H Ozenci, N Taçyildiz, E Unal, G Yavuz, G Deda, D Aysev.   

Abstract

BACKGROUND: Fungal infection represents a growing problem in children with hematologic malignancies. During chemotherapy induced neutropenia, colonization with fungi is considered a major risk factor for subsequent fungal infection. The rates and risk factors for mycotic infections in pediatric oncology patients is undetermined, particularly for centers in developing countries. The aim of this study was to evaluate the rates and risk factors of fungal colonization in children with acute leukemia and lymphoma at one of the major pediatric hematology/oncology centers in Turkey. PROCEDURE: Fifty-two consecutive children newly diagnosed with acute leukemia and lymphoma during intensive remission induction therapy were evaluated for the occurrence of fungal colonization (defined as at least one positive surveillance culture) and infection.
RESULTS: Thirty-six of the 52 patients (69.2%) were colonized by Candida albicans which was the only fungus isolated from surveillance cultures. There were three (5.8%) proven systemic fungal infections: two cases of candidemia and one case of brain abscess with Aspergillus spp. isolated from tissue. All patients with fungal colonization were receiving prophylactic or curative antibiotics. No significant association was found between type of disease and fungal colonization, but there was a significant association with neutropenia.
CONCLUSIONS: Our findings suggest that there is a high rate of fungal colonization in children receiving remission induction therapy for acute leukemia and lymphoma. Limiting the use of antibiotics and instituting antifungal chemoprophylaxis may decrease the rate, while the early initiation of empiric antifungal therapy in patients with fever and suspected mycotic colonization may increase survival in these patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10219335     DOI: 10.1002/(sici)1096-911x(199905)32:5<344::aid-mpo6>3.0.co;2-6

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  8 in total

Review 1.  Role of itraconazole in haematology/oncology.

Authors:  N A Pandya; A A Atra; U Riley; C R Pinkerton
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

Review 2.  Interventions for preventing oral candidiasis for patients with cancer receiving treatment.

Authors:  J E Clarkson; H V Worthington; O B Eden
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

3.  Significance of oral Candida infections in children with cancer.

Authors:  Márta Alberth; László Majoros; Gabriella Kovalecz; Emese Borbás; István Szegedi; Ildikó J Márton; Csongor Kiss
Journal:  Pathol Oncol Res       Date:  2006-12-25       Impact factor: 3.201

Review 4.  Pharmacology of itraconazole.

Authors:  K De Beule; J Van Gestel
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Fecal fungal flora of pediatric healthy volunteers and immunosuppressed patients.

Authors:  H Agirbasli; S A Keceli Ozcan; Gündüz Gedikoğlu
Journal:  Mycopathologia       Date:  2005-06       Impact factor: 2.574

6.  Disseminated mucormycosis in a patient with acute myeloblastic leukemia misdiagnosed as infection by Enterococcus faecium.

Authors:  S Sammassimo; S Mazzotta; M Tozzi; S Gentili; M Lenoci; R Santopietro; A Bucalossi; M Bocchia; F Lauria
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

7.  Management of Invasive Fungal Infections in Pediatric Acute Leukemia and the Appropriate Time for Restarting Chemotherapy.

Authors:  Özlem Tüfekçi; Şebnem Yılmaz Bengoa; Fatma Demir Yenigürbüz; Erdem Şimşek; Tuba Hilkay Karapınar; Gülersu İrken; Hale Ören
Journal:  Turk J Haematol       Date:  2015-04-27       Impact factor: 1.831

8.  Multiple brain abscesses caused by infection with Candida glabrata: A case report.

Authors:  Zifeng Zhu; Zhehao Huang; Zhenshengnan Li; Xianglan Li; Chao Du; Yu Tian
Journal:  Exp Ther Med       Date:  2018-01-04       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.